Lindsay Wheeler Brubaker

Dr. Lindsay Wheeler Brubaker

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
JFJessica Floyd
Jessica Floyd
KDKristen DeSanto
Kristen DeSanto
BBBenjamin G. Bitler
Benjamin G. Bitler
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker

4 May 2023 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
DBDonald Backos
Donald Backos
VNVu T. Nguyen
Vu T. Nguyen
PRPhilip Reigan
Philip Reigan
TYTomomi M Yamamoto
Tomomi M Yamamoto
BBBenjamin Bitler
Benjamin Bitler
BackgroundThe Polycomb Repressor Complex 1 (PRC1) is an epigenetic regulator of differentiation and development, consisting of multiple subunits including RING1, BMI1, and Chromobox. The composition of PRC1 dictates its function and aberrant expression of specific subunits contributes to several diseases including cancer. Specifically, the reader protein Chromobox2 (CBX2) recognizes the repressive modifications including histone H3 lysine 27 tri-methylation (H3K27me3) and H3 lysine 9 dimethylation (H3K9me2). CBX2 is overexpressed in several cancers compared to the non-transformed cell counterparts, it promotes both cancer progression and chemotherapy resistance. Thus, inhibiting the reader function of CBX2 is an attractive and unique anti-cancer approach.Research design & methodsCompared with other CBX family members, CBX2 has a unique A/T-hook DNA binding domain that is juxtaposed to the chromodomain (CD). Using a computational approach, we constructed a homology model of CBX2 encompassing the CD and A/T hook domain. We used the model as a basis for peptide design and identified blocking peptides that are predicted to directly bind the CD and A/T-hook regions of CBX2. These peptides were tested in vitro and in vivo models.ConclusionThe CBX2 blocking peptide significantly inhibited both 2D and 3D growth of ovarian cancer cells, downregulated a CBX2 target gene, and blunted tumor growth in vivo.

8 August 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
LKLucy B. Van Kleunen
Lucy B. Van Kleunen
MAMansooreh Ahmadian
Mansooreh Ahmadian
MPMiriam D. Post
Miriam D. Post
RWRebecca J. Wolsky
Rebecca J. Wolsky
CRChristian Rickert
Christian Rickert
ACAaron Clauset
Aaron Clauset
Ovarian cancer is the deadliest gynecologic malignancy, and therapeutic options and mortality rates over the last three decades have largely not changed. Recent studies indicate that the composition of the tumor immune microenvironment (TIME) influences patient outcomes. To improve spatial understanding of the TIME, we performed multiplexed ion beam imaging on 83 human high-grade serous carcinoma tumor samples, identifying approximately 160,000 cells across 23 cell types. From the 77 of these samples that met inclusion criteria, we generated composition features based on cell type proportions, spatial features based on the distances between cell types, and spatial network features representing cell interactions and cell clustering patterns, which we linked to traditional clinical and IHC variables and patient overall survival (OS) and progression-free survival (PFS) outcomes. Among these features, we found several significant univariate correlations, including B-cell contact with M1 macrophages (OS HR = 0.696; P = 0.011; PFS HR = 0.734; P = 0.039). We then used high-dimensional random forest models to evaluate out-of-sample predictive performance for OS and PFS outcomes and to derive relative feature importance scores for each feature. The top model for predicting low or high PFS used TIME composition and spatial features and achieved an average AUC score of 0.71. The results demonstrate the importance of spatial structure in understanding how the TIME contributes to treatment outcomes. Furthermore, the present study provides a generalizable roadmap for spatial analyses of the TIME in ovarian cancer research.

1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RIRitsuko Iwanaga
Ritsuko Iwanaga
TYTomomi M. Yamamoto
Tomomi M. Yamamoto
KGKarina Gomez
Karina Gomez
LNLily L. Nguyen
Lily L. Nguyen
EWElizabeth R. Woodruff
Elizabeth R. Woodruff
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
Chromobox 2 (CBX2), an epigenetic reader and component of polycomb repressor complex 1, is highly expressed in >75% of high-grade serous carcinoma. Increased CBX2 expression is associated with poorer survival, whereas CBX2 knockdown leads to improved chemotherapy sensitivity. In a high-grade serous carcinoma immune-competent murine model, knockdown of CBX2 decreased tumor progression. We sought to explore the impact of modulation of CBX2 on the tumor immune microenvironment (TIME), understanding that the TIME plays a critical role in disease progression and development of therapy resistance. Exploration of existing datasets demonstrated that elevated CBX2 expression significantly correlated with specific immune cell types in the TIME. RNA sequencing and pathway analysis of differentially expressed genes demonstrated immune signature enrichment. Confocal microscopy and co-culture experiments found that modulation of CBX2 leads to increased recruitment and infiltration of macrophages. Flow cytometry of macrophages cultured with CBX2-overexpressing cells showed increased M2-like macrophages and decreased phagocytosis activity. Cbx2 knockdown in the Trp53-null, Brca2-null ID8 syngeneic murine model (ID8 Trp53−/−Brca2−/−) led to decreased tumor progression compared with the control. NanoString immuno-oncology panel analysis suggested that knockdown in Cbx2 shifts immune cell composition, with an increase in macrophages. Multispectral immunohistochemistry (mIHC) further confirmed an increase in macrophage infiltration. Increased CBX2 expression leads to recruitment and polarization of protumor macrophages, and targeting CBX2 may serve to modulate the TIME to enhance the efficacy of immune therapies. Significance: CBX2 expression correlates with the TIME. CBX2 modulation shifts the macrophage population, potentially leading to an immunosuppressive microenvironment, highlighting CBX2 as a target to improve efficacy of immunotherapy.

4 October 2023 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
CPChristianne Persenaire
Christianne Persenaire
DSDaniel L. Spinosa
Daniel L. Spinosa
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
CLCarolyn J. Lefkowits
Carolyn J. Lefkowits

4 November 2024
Verified
Other
Open access
PDF file
LKLucy B. Van Kleunen
Lucy B. Van Kleunen
MAMansooreh Ahmadian
Mansooreh Ahmadian
MPMiriam D. Post
Miriam D. Post
RWRebecca J. Wolsky
Rebecca J. Wolsky
CRChristian Rickert
Christian Rickert
ACAaron Clauset
Aaron Clauset
Fig S16. Survival curves. Kaplan-Meier survival curves for (A) survival and (B) recurrence outcomes.